Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138

Thérapie
Mark J Millan, Mauricette Brocco

Abstract

In vivo animal models are indispensable both for clarifying the pathological bases of schizophrenia, and for evaluating the potential benefits and disadvantages of novel therapy. Procedures that model mnemonic impairment are of particular interest since currently-available drugs do little to improve cognitive symptoms: this is hardly surprising, in fact, since most of them potently antagonise histamine H(1), muscarinic, and/or alpha(1)-adrenergic receptors. Further, their blockade of D(2) receptors likewise compromises cognitive performance. By contrast, D(3) receptor antagonism improves certain cognitive domains, suggesting that preferential antagonism of D(3) vs. D(2) receptors may permit enhanced effectiveness against cognitive dysfunction. The novel agent, S33138, possesses such an "optimised" profile and shows a unique and broad-based pattern of pro-cognitive properties in rodents and primates, in the absence of extrapyramidal and metabolic side-effects. The present article surveys the preclinical pharmacology of S33138. It also reviews developmental and genetic risk factors for schizophrenia and their experimental modeling in rodents, with a particular emphasis on sensorimotor gating and cognitive deficits.

References

Aug 1, 1993·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·B K LipskaD R Weinberger
Jul 1, 1997·Progress in Neurobiology·A Hashimoto, T Oka
Dec 24, 1997·Physiology & Behavior·H SteinerD Accili
May 20, 1998·Schizophrenia Research·B A EllenbroekA R Cools
May 1, 1999·The Journal of Biological Chemistry·E HajduchH S Hundal
Sep 25, 1999·Physiology & Behavior·V P Bakshi, M A Geyer
Oct 9, 1999·Pharmacology, Biochemistry, and Behavior·A J Goudie, J A Smith
Mar 4, 2000·Behavioural Brain Research·A Becker, G Grecksch
Feb 7, 2001·Psychopharmacology·N R Mirza, I P Stolerman
Aug 16, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·B K Lipska, D R Weinberger
Sep 16, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Y NodaT Nabeshima
Sep 30, 2000·Brain Research. Brain Research Reviews·P C MoserP M Moran
Oct 13, 2000·The European Journal of Neuroscience·K Q DoM Cuénod
Dec 5, 2000·Behavioural Pharmacology·B A Ellenbroek, A R Cools
Oct 20, 2001·Behavioural Brain Research·L BacciottiniP Blandina
Oct 30, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·M L WadenbergS Kapur
Dec 12, 2001·Endocrine Reviews·N Ben-Jonathan, R Hnasko
Dec 26, 2001·Proceedings of the National Academy of Sciences of the United States of America·D J GerberS Tonegawa
Mar 14, 2002·Proceedings of the National Academy of Sciences of the United States of America·Hui LiuMaria Karayiorgou
Apr 2, 2002·The American Journal of Psychiatry·Michael J SernyakRobert Rosenheck
Jul 3, 2002·Molecular and Cellular Neurosciences·Fabrice AngoLaurent Fagni
Jul 3, 2002·Nature Reviews. Neuroscience·Mark G Baxter, Elisabeth A Murray
Oct 5, 2002·Proceedings of the National Academy of Sciences of the United States of America·Ilya ChumakovJohn Realson
Nov 14, 2002·Behavioural Brain Research·Elisabeth W P M DaenenJan M Van Ree

❮ Previous
Next ❯

Citations

Nov 7, 2012·Naunyn-Schmiedeberg's Archives of Pharmacology·Gerhard GrossKarla U Drescher
Jun 25, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Shinichiro NakajimaAriel Graff-Guerrero
Dec 27, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Mark J Millan
Oct 28, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David J G WatsonKevin C F Fone
Aug 2, 2011·Journal of Physiology, Paris·Olivier BonnotNathalie Coulon
Jan 3, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·David J G WatsonKevin C F Fone
Sep 17, 2008·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Florence Loiseau, Mark J Millan
Apr 1, 2011·British Journal of Pharmacology·C A JonesK C F Fone
Mar 6, 2010·Annals of the New York Academy of Sciences·Christian A Heidbreder, Amy H Newman
Dec 5, 2012·NeuroImage·Graham E SearleRoger N Gunn
Jul 29, 2010·The International Journal of Neuropsychopharmacology·Mark J MillanJay S Schneider
May 3, 2016·Expert Opinion on Drug Discovery·Antoni CortésVicent Casadó
Nov 10, 2009·Current Opinion in Pharmacology·Roberto Maggio, Mark J Millan
Oct 21, 2016·Frontiers in Neuroscience·Samuele MaramaiMargherita Brindisi
Oct 3, 2018·Cerebral Cortex·Kirsten M LynchUNKNOWN Pediatric Imaging, Neurocognition and Genetics Study
Oct 19, 2016·Developmental Psychobiology·Kimberly Cuevas, Amy Giles
Nov 12, 2015·Child Development Perspectives·Rebecca L Gómez, Jamie O Edgin
Aug 19, 2016·The American Journal of Clinical Nutrition·Patricia J Bauer, Jessica A Dugan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.